| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
32 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
46 |
| Net Income (TTM) (Millions $) |
4 |
| Cash Flow (TTM) (Millions $) |
2 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
La Jolla Pharmaceutical Company is a biopharmaceutical company based in San Diego, California. It focuses on the research, development, and commercialization of innovative therapies for life-threatening diseases. It primarily specializes in the field of auto-immune diseases and inflammation.
The company's main product is a drug called GIAPREZA (angiotensin II), which is approved for the treatment of critically ill patients with septic or other distributive shock. GIAPREZA is used to increase blood pressure in these patients who do not respond to conventional treatments.
La Jolla Pharmaceutical Company also has a pipeline of potential future therapies, including LJPC-401 for hereditary hemochromatosis and LJPC-0118 for severe malaria. It consistently invests in research and development to expand its product portfolio and improve patient outcomes.
Overall, La Jolla Pharmaceutical Company is dedicated to making a positive impact in the field of biopharmaceuticals by developing innovative treatments for life-threatening conditions and improving patients' lives.
Company Address: 201 Jones Road Waltham 2451 MA
Company Phone Number: 715-3600 Stock Exchange / Ticker: NASDAQ LJPC
|
%
45.74%